

AMENDMENT TO THE CLAIMS

Please amend the claims as follows, without prejudice or disclaimer. This listing of the claims replaces any prior listings of the claims.

1. (Currently amended) A method for treating ~~cancer~~ melanoma comprising:
 - a) administering to a host a composition containing a ~~tumor antigen, fragment thereof or~~ nucleic acid encoding the a tumor antigen such that the host develops an immune response against the tumor antigen; and,
 - b) subsequently administering a therapeutically effective amount of interferon to the host ~~a high dose of a cytokine~~;whereby the combination of steps a) and b) provides an enhanced T cell response in the host relative to that which occurs following step a) alone.
2. (Cancelled) *The method of claim 1 wherein the tumor antigen is administered as a polypeptide or peptide.*
3. (Cancelled) *The method of claim 1 wherein the composition comprises a nucleic acid encoding a tumor antigen.*
4. (Currently Amended) The method of claim 3 1 wherein the nucleic acid is contained within a plasmid or a viral vector.
5. (Original) The method of claim 4 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
6. (Original) The method of claim 5 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, MVA, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
7. (Original) The method of claim 6 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
8. (Original) The method of claim 1 wherein the cytokine is IFN.
9. (Original) The method of claim 8 wherein the cytokine is IFN- α .
10. (Original) The method of claim 9 wherein the cytokine is IFN- α 2b.
11. (Original) The method of claim 1 wherein the tumor antigen is selected from the group consisting of gp100, MART-1/Melan A, gp75/TRP-1, tyrosinase, NY-ESO-1,

melanoma proteoglycan, a MAGE antigen, a BAGL antigen, a GAGE antigen, RAGE antigen, N-acetylglucosaminyltransferase-V, p15, β -catenin, MUM-1, cyclin dependent kinase-4, p21-ras, BCR-abl, p53, p185 HER2/neu, epidermal growth factor receptor, carcinoembryonic antigen, modified carcinoembryonic antigen, carcinoma-associated mutated mucins, an Epstein Barr Virus EBNA gene product, papilloma virus E7, papilloma virus E6, prostate specific antigen, prostate specific membrane antigen, KSA, kinesin 2, HIP-55, TGF β -1 anti-apoptotic factor, tumor protein D52, H1FT, an NY-BR antigen, fragments thereof, and derivatives thereof.

12. (Original) The method of claim 11 wherein the tumor antigen is selected from the group consisting of gp100, MAGE-1, MAGE-2, MAGE-3, MAGE-4, MAGE-6, MAGE-12, MAGE-51, GAGE-1, GAGE-2, RAGE-1, NY-BR-1, NY-BR-62, NY-BR-75, NY-BR-85, NY-BRP-87, and NY-BR-96.
13. (Original) The method of claim 12 wherein the tumor antigen is gp100.
14. (Currently amended) The method of claim 1 wherein the composition comprises an poxviral vector encoding a tumor antigen or a fragment thereof and the cytokine is a T cell activating cytokine.
15. (Original) The method of claim 14 wherein poxviral vector is an ALVAC vector and the T cell activating cytokine is IFN.
16. (Original) The method of claim 15 wherein the T cell activating cytokine is IFN α .
17. (Original) The method of claim 16 wherein the T cell activating cytokine is IFN α 2b.
18. (Original) The method of claim 17 wherein IFN α 2b is administered at at least 10 MU/m²/d IV at least two times per week for at least two weeks.
19. (Original) The method of claim 18 wherein IFN α 2b is administered at at least 10 MU/m²/d IV at least three times per week for at least two weeks.
20. (Original) The method of claim 19 wherein IFN α 2b is administered at at least 10 MU/m²/d IV at least four times per week for at least two weeks.
21. (Original) The method of claim 20 wherein IFN α 2b is administered at at least 10 MU/m²/d IV at least five times per week for at least two weeks.
22. (Original) The method of claim 21 wherein IFN α 2b is administered at at least 20 MU/m²/d IV at least five times per week for at least four weeks.